Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 29:10:993436.
doi: 10.3389/fbioe.2022.993436. eCollection 2022.

The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges

Min He  1   2 , Tianyi Chen  1 , Yuhuan Lv  1 , Peiyang Song  1 , Bo Deng  1 , Xuewen Guo  1 , Shunli Rui  1 , Johnson Boey  3 , David G Armstrong  4 , Yu Ma  1 , Wuquan Deng  1
Affiliations
Review

The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges

Min He et al. Front Bioeng Biotechnol. .

Abstract

The frequency of chronic cutaneous wounds are sharply increasing in aging populations. Patients with age-related diseases, such as diabetes, tumors, renal failure and stroke are prone to soft tissue and skin injury, compounded by slowed healing in aging. Imbalance of wound inflammation, loss of growth factor secretion, and impairment of tissue repair abilities are all possible reasons for failed healing. Therefore, it is vital to explore novel approaches to accelerate wound healing. Platelet-rich plasma (PRP) as a cell therapy has been widely applied for tissue repair and regeneration. PRP promotes wound healing by releasing antimicrobial peptides, growth factors and micro-RNAs. Medical evidence indicates that autologous platelet-rich plasma (au-PRP) can promote wound healing effectively, safely and rapidly. However, its clinical application is usually restricted to patients with chronic cutaneous wounds, generally because of other severe complications and poor clinical comorbidities. Allogeneic platelet-rich plasma (al-PRP), with abundant sources, has demonstrated its superiority in the field of chronic wound treatment. Al-PRP could overcome the limitations of au-PRP and has promising prospects in clinical applications. The aim of this review is to summarize the current status and future challenges of al-PRP in chronic cutaneous wound management. We also summarized clinical cases to further describe the application of al-PRP for chronic wounds in clinical practice.

Keywords: allogeneic platelet-rich plasma; current perspectives; diabetic foot ulcer; future challenges; wound healing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
A schematic diagram of allogenic PRP treatment. There are two different preparation methodology of allogenic PRP donated from healthy volunteers: manual platelet separation with venous whole blood or platelets apheresis with automatic machine only collected platelets. The allogenic platelet rich gel was used to diabetic foot ulcer after activation by with a mixed solution of thrombin and calcium.
FIGURE 2
FIGURE 2
The diabetic lower extremity ulcer successfully healed with allogenic PRP. The patient with diabetic lower extremity ulcer was topical administrated with allogenic PRP. After 21-day treatment, the ulcer was completely healed.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abouelnasr K., Hamed M., Lashen S., El-Adl M., Eltaysh R., Tagawa M. (2017). Enhancement of abdominal wall defect repair using allogenic platelet-rich plasma with commercial polyester/cotton fabric (Damour) in a canine model. J. Vet. Med. Sci. 79 (7), 1301–1309. 10.1292/jvms.17-0139 - DOI - PMC - PubMed
    1. Ahmed M., Reffat S., Hassan A., Eskander F. (2017). Platelet rich plasma for the treatment of clean diabetic foot ulcers. Ann. Vasc. Surg. 38, 206–211. 10.1016/j.avsg.2016.04.023 - DOI - PubMed
    1. Akbarzadeh S., McKenzie M. B., Rahman M. M., Cleland H. (2021). Allogeneic platelet-rich plasma: Is it safe and effective for wound repair? Eur. Surg. Res. 62 (1), 1–9. 10.1159/000514223 - DOI - PubMed
    1. Anitua E. (1999). Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int. J. Oral Maxillofac. Implants 14, 529 - PubMed
    1. Anitua E., Zalduendo M., Troya M., Alkhraisat M. H., Blanco-Antona L. A. (2022). Platelet-rich plasma as an alternative to xenogeneic sera in cell-based therapies: A need for standardization. Int. J. Mol. Sci. 23 (12), 6552. 10.3390/ijms23126552 - DOI - PMC - PubMed